Daijiworld Media Network - Toronto

Toronto, Nov 13: In what experts are calling a breakthrough in the global fight against malaria, a new next-generation drug candidate — GanLum (ganaplacide/lumefantrine, KLU156) — has shown a 97% cure rate in Phase 3 clinical trials, slightly outperforming the current gold standard Artemisinin Combination Therapy (ACT).

The randomised controlled trial, conducted across 12 Sub-Saharan African nations and involving over 1,600 participants, demonstrated GanLum’s superior efficacy against Plasmodium falciparum, the most deadly malaria parasite responsible for nearly all malaria-related deaths worldwide.

The results were unveiled at the American Society for Tropical Medicine and Health (ASTMH) annual conference in Toronto. According to pharmaceutical giant

See Full Page